IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
31.96
-0.93 (-2.83%)
At close: Oct 30, 2026, 4:00 PM EDT
31.95
-0.01 (-0.03%)
After-hours: Oct 30, 2026, 7:30 PM EDT
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $8.86M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $234.13M, up 3,244.67% year-over-year. In the year 2025, IDEAYA Biosciences had annual revenue of $218.71M with 3,024.43% growth. That makes IDEAYA Biosciences the 16,334th largest company in the world by revenue and 2,785th in the United States.
Revenue (ttm)
$234.13M
Revenue Growth
+3,244.67%
P/S Ratio
13.17
Revenue / Employee
$1,614,669
Employees
145
Market Cap
3.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 218.71M | 211.71M | 3,024.43% |
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Acadia Pharmaceuticals | 1.14B |
| Telix Pharmaceuticals | 890.79M |
| Nurix Therapeutics | 701.94M |
| Tarsus Pharmaceuticals | 606.33M |
| Xenon Pharmaceuticals | 7.50M |
| Denali Therapeutics | 3.60M |
IDYA News
- 1 day ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 1 day ago - Ideaya Biosciences price target lowered to $44 from $50 at Mizuho - TheFly
- 8 days ago - Ideaya Biosciences announces updated clinical results from IDE849 trial - TheFly
- 8 days ago - IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas - PRNewsWire
- 12 days ago - Ideaya Biosciences presents updated data from three darovasertib studies - TheFly
- 12 days ago - IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma - PRNewsWire
- 15 days ago - Ideaya Biosciences initiated with an Outperform at William Blair - TheFly
- 17 days ago - Ideaya Biosciences resumed with a Buy at Stifel - TheFly